193 related articles for article (PubMed ID: 15120037)
1. The hollow fibre model in cancer drug screening: the NCI experience.
Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA
Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037
[TBL] [Abstract][Full Text] [Related]
2. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
3. The hollow fiber assay: continued characterization with novel approaches.
Hall LA; Krauthauser CM; Wexler RS; Hollingshead MG; Slee AM; Kerr JS
Anticancer Res; 2000; 20(2A):903-11. PubMed ID: 10810375
[TBL] [Abstract][Full Text] [Related]
4. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
Peterson JK; Houghton PJ
Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo.
Suggitt M; Swaine DJ; Pettit GR; Bibby MC
Clin Cancer Res; 2004 Oct; 10(19):6677-85. PubMed ID: 15475458
[TBL] [Abstract][Full Text] [Related]
6. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
7. Angiogenesis in the hollow fiber tumor model influences drug delivery to tumor cells: implications for anticancer drug screening programs.
Phillips RM; Pearce J; Loadman PM; Bibby MC; Cooper PA; Swaine DJ; Double JA
Cancer Res; 1998 Dec; 58(23):5263-6. PubMed ID: 9850044
[TBL] [Abstract][Full Text] [Related]
8. Development of a modified hollow fibre assay for studying agents targeting the tumour neovasculature.
Shnyder SD; Hasan J; Cooper PA; Pilarinou E; Jubb E; Jayson GC; Bibby MC
Anticancer Res; 2005; 25(3B):1889-94. PubMed ID: 16158922
[TBL] [Abstract][Full Text] [Related]
9. Benzethonium chloride: a novel anticancer agent identified by using a cell-based small-molecule screen.
Yip KW; Mao X; Au PY; Hedley DW; Chow S; Dalili S; Mocanu JD; Bastianutto C; Schimmer A; Liu FF
Clin Cancer Res; 2006 Sep; 12(18):5557-69. PubMed ID: 17000693
[TBL] [Abstract][Full Text] [Related]
10. In vitro assays of chemotherapeutic sensitivity.
Carney DN; Winkler CF
Important Adv Oncol; 1985; ():78-103. PubMed ID: 3916747
[TBL] [Abstract][Full Text] [Related]
11. Chemoinformatic analysis of NCI preclinical tumor data: evaluating compound efficacy from mouse xenograft data, NCI-60 screening data, and compound descriptors.
Wallqvist A; Huang R; Covell DG
J Chem Inf Model; 2007; 47(4):1414-27. PubMed ID: 17555311
[TBL] [Abstract][Full Text] [Related]
12. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models.
Voskoglou-Nomikos T; Pater JL; Seymour L
Clin Cancer Res; 2003 Sep; 9(11):4227-39. PubMed ID: 14519650
[TBL] [Abstract][Full Text] [Related]
13. New anticancer agents: in vitro and in vivo evaluation.
Zips D; Thames HD; Baumann M
In Vivo; 2005; 19(1):1-7. PubMed ID: 15796152
[TBL] [Abstract][Full Text] [Related]
14. Human tumor testsystems: a new screening approach.
Kraemer HP; Sedlacek HH
Behring Inst Mitt; 1986 Jun; (80):103-12. PubMed ID: 3753367
[TBL] [Abstract][Full Text] [Related]
15. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials.
Johnson JI; Decker S; Zaharevitz D; Rubinstein LV; Venditti JM; Schepartz S; Kalyandrug S; Christian M; Arbuck S; Hollingshead M; Sausville EA
Br J Cancer; 2001 May; 84(10):1424-31. PubMed ID: 11355958
[TBL] [Abstract][Full Text] [Related]
16. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
17. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
18. The hollow fibre model--facilitating anti-cancer pre-clinical pharmacodynamics and improving animal welfare.
Suggitt M; Cooper PA; Shnyder SD; Bibby MC
Int J Oncol; 2006 Dec; 29(6):1493-9. PubMed ID: 17088988
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
20. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity: part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity.
Hartley JA; Spanswick VJ; Brooks N; Clingen PH; McHugh PJ; Hochhauser D; Pedley RB; Kelland LR; Alley MC; Schultz R; Hollingshead MG; Schweikart KM; Tomaszewski JE; Sausville EA; Gregson SJ; Howard PW; Thurston DE
Cancer Res; 2004 Sep; 64(18):6693-9. PubMed ID: 15374986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
